arXiv:2607. 19237v1 Announce Type: new Abstract: Designing small molecule ligands that bind with high affinity to specific protein pockets is a fundamental goal in drug discovery, as small molecules constitute a major fraction of approved therapeutics.
arXiv:2506. 14488v2 Announce Type: replace-cross Abstract: Structure-based drug design (SBDD) models are central to modern pharmaceutical research, enabling the rational exploration of protein-ligand interactions at atomic resolution.
arXiv:2607. 03787v1 Announce Type: new Abstract: Accurately modeling biomolecular interactions is a central bottleneck in biology and therapeutic discovery.
arXiv:2605.08954v2 Announce Type: replace-cross Abstract: Molecular optimization in drug discovery aims to discover molecules with improved target properties, but practical lead optimization often re...
The paper introduces ReGeoDTA, a framework that preserves chemical heterogeneity and continuous geometric relationships in drug and protein representations to improve drug–target affinity prediction. Experiments on three benchmark datasets show that maintaining representation fidelity consistently enhances predictive accuracy across various DTA architectures, while degrading representations harms performance and cannot be recovered by more complex downstream models. The study highlights representation fidelity as a key upstream design principle for accurate and generalizable affinity prediction.
SpecOpt is a new molecular design task that optimizes the binding specificity of existing drugs by making constrained structural modifications. The method uses an agentic framework that docks a compound against its intended target and known off‑targets, compares residue‑aware atom‑protein contacts, and feeds the differential interactions to a large language model to propose changes. On a benchmark of 915 compounds, SpecOpt increased the target‑off‑target binding gap for 84.8% of cases while preserving drug‑like properties and structural similarity.
arXiv:2607. 18144v1 Announce Type: cross Abstract: Structure-based drug design (SBDD) leverages the 3D structure of protein targets, often complemented by other spatial constraints, to generate candidate binding molecules.
NEAT-POCKET is a pocket‑conditioned extension of the autoregressive NEAT model that generates 3D molecules atom by atom within protein binding pockets, maintaining atom permutation invariance and explicitly modeling hydrogen atoms. It outperforms existing baselines on the CrossDocked and SPINDR datasets, achieving competitive structure‑based generation performance while sampling significantly faster. The model also supports pocket‑conditioned fragment completion, a capability directly useful for lead optimization and scaffold elaboration in drug design.
Drug discovery and development is time-consuming and resource-intensive, motivating computational approaches such as diffusion models for de novo drug design. Many such models follow the structure-based drug design (SBDD) paradigm, generating molecules to fit a target binding pocket.
arXiv:2606. 14159v1 Announce Type: new Abstract: Protein-ligand binding affinity (PLA) prediction is critical in drug discovery.
arXiv:2608. 09099v1 Announce Type: new Abstract: Quantitative estimation of protein-ligand binding affinity from three-dimensional complex structures is a fundamental task in structure-based computational chemistry and molecular modeling.
arXiv:2607. 12349v1 Announce Type: new Abstract: Drug discovery and development is time-consuming and resource-intensive, motivating computational approaches such as diffusion models for de novo drug design.
arXiv:2606. 05198v1 Announce Type: cross Abstract: Nucleic acids are increasingly recognized as therapeutic targets beyond conventional protein-centered drug discovery, yet accurate and efficient docking of small molecules to nucleic acid structures remains challenging.